Inside the American Pharmaceutical Pipeline

How Drug Development Begins

Before any pill reaches a pharmacy shelf, scientists spend years in the laboratory searching for compounds with therapeutic potential. This early stage — called preclinical research — involves identifying a biological target (such as a protein linked to a disease), screening thousands of chemical compounds, and narrowing the field to those that show promise without obvious toxicity.

Researchers conduct lab tests and animal studies to gather initial safety and efficacy data. Only a small fraction of candidates advance. If a compound looks viable, the drug developer files an Investigational New Drug (IND) application with the Food and Drug Administration, requesting permission to begin testing in humans. The FDA reviews the IND to confirm that the proposed trials are reasonably safe to proceed.

Clinical Trials: Testing in Humans

Clinical trials are the backbone of the pharmaceutical pipeline. They are conducted in three sequential phases, each with a distinct purpose:

• Phase I enrolls a small group of volunteers — typically 20 to 100 people — primarily to assess safety, dosage tolerance, and how the drug behaves in the human body.
• Phase II expands to hundreds of participants who have the condition being treated. The focus shifts to whether the drug actually works and to identifying common side effects.
• Phase III involves thousands of patients across multiple sites. These large, randomized, controlled trials generate the statistically robust evidence the FDA requires before considering approval.

Each phase must meet defined endpoints before the next can begin. Trials that reveal serious safety problems are halted. This attrition is intentional — the system is designed to filter out harmful or ineffective compounds before they reach patients at scale.

The FDA Review and Approval Process

Once a sponsor company completes Phase III trials, it compiles all preclinical and clinical data into a New Drug Application (NDA) and submits it to the FDA's Center for Drug Evaluation and Research (CDER). This submission can run hundreds of thousands of pages.

FDA reviewers — including physicians, pharmacologists, statisticians, and chemists — evaluate whether the drug is safe and effective for its intended use and whether the proposed labeling accurately reflects the evidence. The standard review target is about 10 to 12 months. For drugs addressing serious unmet medical needs, the FDA offers expedited programs such as Breakthrough Therapy or Priority Review designations that can shorten this timeline.

Approval is not guaranteed. The FDA may issue a Complete Response Letter requesting additional data before it will act favorably. If approved, the agency specifies the conditions of use — including dosage, patient population, and required warnings — that appear on the drug's official label. For broader context on how the FDA fits into the U.S. healthcare landscape, see our overview of the American healthcare system.

From Manufacturer to Pharmacy

Approval does not automatically mean a drug is accessible to patients. Getting it from factory to pharmacy involves a multi-layer supply chain. Pharmaceutical manufacturers produce drugs under strict Good Manufacturing Practice (GMP) standards enforced by the FDA. Products then move through large wholesale distributors — companies that aggregate inventory and deliver to hospitals, retail pharmacies, and clinics nationwide.

Layered on top of this logistics infrastructure are Pharmacy Benefit Managers (PBMs), which negotiate drug prices and formulary placement on behalf of insurers and employers. PBMs significantly influence which drugs patients can access affordably and at which pharmacies. The interplay between manufacturers, wholesalers, PBMs, and insurers is a major driver of the prices Americans pay — and a subject of considerable policy debate. This supply chain shares structural parallels with other distribution-heavy industries; for comparison, see our look at U.S. freight and trucking.

Post-Market Surveillance and Ongoing Safety

FDA approval marks a milestone, not an endpoint. Once a drug is in widespread use, the real-world population of patients is far larger and more diverse than any clinical trial. Rare adverse events that weren't apparent in trials may only emerge at scale.

The FDA operates MedWatch, a voluntary reporting system through which healthcare providers and patients can submit reports of unexpected side effects or product quality problems. Manufacturers are also required to conduct post-market safety studies and submit periodic safety reports to the FDA.

If new evidence reveals that a drug's risks outweigh its benefits, the FDA has authority to require updated warnings, restrict use to specific patient groups, or — in serious cases — require market withdrawal. Some drugs are also approved with a Risk Evaluation and Mitigation Strategy (REMS), a formal safety program that may require patient enrollment, prescriber certification, or pharmacy restrictions to ensure the drug is used appropriately.

This article is for informational and educational purposes only. It does not constitute medical or legal advice. Consult a qualified healthcare professional for guidance related to any specific medical condition or treatment.